Skip to content

Dolutegravir

Two dolutegravir products sit on this shelf: Tivicay, the single-ingredient 50 mg tablet, and Viropil, which adds lamivudine and tenofovir disoproxil in one combination tablet for HIV-1 infection.

Tivicay

Human Immunodeficiency Virus 1 (HIV-1) Infection

50mg

Dolutegravir tablets for HIV-1 infection. It blocks an enzyme the virus needs to copy itself into cells.

From$8.18/ tabletView

Viropil

Human Immunodeficiency Virus 1 (HIV-1) Infection

50mg + 300mg + 300mg

Dolutegravir and lamivudine tablets for HIV-1 infection. It blocks two different steps in the HIV lifecycle.

From$8.88/ tabletView

Key points

  • Dolutegravir is an integrase inhibitor that reduces the amount of HIV in the blood as part of antiretroviral treatment.
  • Tivicay contains dolutegravir alone; Viropil pairs it with lamivudine and tenofovir disoproxil in a single tablet.
  • Dolutegravir has timing interactions with products containing aluminium, magnesium, calcium or iron, and missed doses can promote viral resistance.

Common questions about Dolutegravir

Why does Viropil contain three active ingredients while Tivicay contains one?

Tivicay is dolutegravir on its own, which suits people whose regimen includes other antiretrovirals. Viropil combines dolutegravir with lamivudine and tenofovir disoproxil in one tablet, so a person taking all three molecules needs only one product. Both are listed under HIV Management.

What should I know about taking dolutegravir with antacids or mineral supplements?

Dolutegravir binds to aluminium, magnesium, calcium and iron in the gut, which can reduce how much of the medicine your body absorbs. The label sets timing rules around products containing these minerals. Stopping or skipping doses of any dolutegravir-containing tablet can allow HIV to develop resistance, so consistent use matters.

Further reading